Omega Diagnostics Share Discussion Threads

[barrywhit] 19/8/2019 07:58

Perhaps delaying results also extends the closed period, so the Directors have a reason to not put their hands in their pockets and buy a few shares....LOL

[upomega] 17/8/2019 15:29

And your point being ?????????

[buywell3] 17/8/2019 15:16

there are none so blind as they who cannot see

apart from those who refuse to open their eyes

[upomega] 17/8/2019 12:00

Any posts on this board that promotes Omega is a positive, but the company at present seem to be signing their own death warrant.
Question again .why has it taken six months to produce a set of accounts and why isn't the house broker/advisors doing a better pr job. What has happened to the recent non exec director designed to take over as chairman.
People should be clambering over themselves to invest in this not the opposite?????.INMO

[gwr7] 17/8/2019 11:29

Don't be hasty Hyper.
If Hurbinson bats for Omega on Monday, can someone ask him what he's coated with and whether they can patent it?
He's got the edge on Teflon.

[bomber13] 17/8/2019 09:45

Excellent finds Hyperboreus , I hugely appreciate your input .

[hyperboreus] 17/8/2019 08:39

No more from me on this bulletin board, I shall leave it to the intellectuals from now on!

[upomega] 17/8/2019 08:14

What's interesting.apart from highlighting inept behaviour by Onega,s pr team

[hyperboreus] 17/8/2019 07:32

Interesting video put out recently by the South African Medical Unit (SAMU) which is connected to Medecins Sans Frontieres which is definitely giving the 'thumbs up' to Omega's VISITECT® CD4 ADVANCED DISEASE TEST



The following link gives more info regarding the competition and pricing of the alternatives in the market:

[upomega] 17/8/2019 00:21

maybe going forward the company could issue separate Rns announcements. Inmo the good news has been clouded by the mystery surrounding the accounts being delayed. Personally I cannot understand why these accounts were not published in june.
I am unable to attend the investors meeting, but will be contacting the company for that reason . Hopefully this will be answered at the presentation and someone will post on this message board.
INMO pr needs to be handled a little better.On paper I have lost a lot of money which I feel would have been less if pr had been handled a little better in releasing news and publication of accounts in a timely manner.

[barrywhit] 16/8/2019 19:10

Just read the RNS, reads OK. Strange about the results being deferred, heading in the right direction.

[upomega] 16/8/2019 15:52

Not a bad write up in the Scotsman. I think people have missed the positives here with China and sales materialising for CD4. All we need now is ERP validation for CD4200. Also the company is still recruiting which is generally a good sign inmo

[upomega] 16/8/2019 15:09

I think the pr company needs to be more active here. None of the write ups on the newswire,s are mentioning the positive news which accompanied the rns

[hyperboreus] 16/8/2019 15:08

'The Company's cash position at 31 March 2019 was net utilisation of £0.74m of the £2m overdraft facility.'

The gross fundraising of £634,795 took place on 22 May 2019 nearly 2 months after the year end but we have no idea of knowing what the Company's cash position is as of today.

Very confusing and impossible to know just what has changed since 8 August when Omega announced that they were holding an 'Investor Briefing' for all investors next Monday
'accompanying the full year results for the year ended 31 March 2019.'

For what it is worth finnCapp (ODX house broker) seem to be putting a positive spin on the announcement:

'More exciting and relevant to the investment case, however, is confirmation that it has received two purchase orders for VISITECT CD4 in Nigeria and for Food Detective in China, worth c.£0.5m. Whilst the Nigerian order is conditional on receiving approval, which is in process, we expect this to represent the beginning of the roll-out of its VISITECT CD4 range that will ultimately be bought at scale by NGOs.'

[buywell3] 16/8/2019 15:08

Check the number of employees

Compare it to revenue of others and profit



Easy to see ODX are WAY OVER STAFFED

Need to reduce headcount to circa 70 people TOPS

[likitorma] 16/8/2019 14:33

What the market is not liking is the high utilisation of the overdraft when they literally just raised money recently.

[dibs61] 16/8/2019 14:02

From what I recall the number one objective of the board was to crystallise short term shareholder value. This announcement does not deliver on that no.1 objective. Maybe that has got something to do with the ‘commercial discussions’ etc

[upomega] 16/8/2019 13:43

it looks like the market doesn't like the rns. maybe the company can somehow embellish on matters a little further

[tickboo] 16/8/2019 13:24

Surely CD4 will generate decent revenues!?

[buywell3] 16/8/2019 13:02

buywell years ago said Food Intolerance was the only decent part of ODX


IMO the major shareholders should get the rest sold off ASAP


Reduce headcount by a minimum of 50%


Then he might invest

[upomega] 16/8/2019 12:52

Personally I am not too worried about the results being delayed. I think we all know that they were never going to be that wonderful. INMO it,s what transpires now. I think the Ceo has delivered on everything that he has said he would do. Maybe we are going to get news on EPRD validation for cd4200. Which would be the final piece in the jigsaw. I just hope an opportunist bid doesn't come in now before the company can get the share price up from these levels.

[hyperboreus] 16/8/2019 11:24

Eh, give em a good grilling Arthur, assuming you are still going that is?